Disease on EC 2.4.2.30 - NAD+ ADP-ribosyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
miR-520 promotes DNA-damage-induced trophoblast cell apoptosis by targeting PARP1 in recurrent spontaneous abortion (RSA).
Acidosis
Activation of poly(ADP-ribose) polymerase in severe hemorrhagic shock and resuscitation.
Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.
Acute Kidney Injury
5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats.
Effect of poly(ADP-ribose) polymerase inhibition on outer medullary hypoxic damage.
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
Inhibition of Poly(ADP-Ribose) Polymerase Attenuates Acute Kidney Injury in Sodium Taurocholate-Induced Acute Pancreatitis in Rats.
Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats.
Inhibition of Poly-(ADP-Ribose) Polymerase Protects the Kidney in a Canine Model of Endotoxic Shock.
Poly (ADP-ribose) polymerase as a potential target for the treatment of acute renal injury caused by lipopolysaccharide.
Poly(ADP-ribose) polymerase 1 activation links ischemic acute kidney injury to interstitial fibrosis.
Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury.
Poly(ADP-ribose) polymerase-mediated cell injury in acute renal failure.
Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis?
Role of poly (ADP-ribose) polymerase-1 and cytokines in acute renal injury in elderly Chinese patients with diabetes mellitus.
Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury.
Acute Lung Injury
Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model.
Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury.
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.
Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.
Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice.
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-?B-mediated inflammatory response.
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.
The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice.
Adenocarcinoma
Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer.
Annonaceous acetogenin mimic AA005 induces cancer cell death via apoptosis inducing factor through a caspase-3-independent mechanism.
Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.
Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7).
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population.
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
DNA Damage Repair Alterations are Frequent in Prostatic Adenocarcinomas with Focal Pleomorphic Giant Cell Features.
Dysregulation of PARP1 is involved in development of Barrett's esophagus.
Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori.
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer.
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer.
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Prodigiosin-induced apoptosis in human colon cancer cells.
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion.
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines.
Adenocarcinoma of Lung
ATM deficiency is associated with sensitivity to PARP1 and ATR inhibitors in lung adenocarcinoma.
Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells.
Erucin, a new promising cancer chemopreventive agent from rocket salads, shows anti-proliferative activity on human lung carcinoma A549 cells.
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Reduced tumor burden through increased oxidative stress in lung adenocarcinoma cells of PARP-1 and PARP-2 knockout mice.
The Joint Effect of hOGG1, APE1, and ADPRT Polymorphisms and Cooking Oil Fumes on the Risk of Lung Adenocarcinoma in Chinese Non-Smoking Females.
Adenoma
Effects of cumene hydroperoxide on adenosine diphosphate ribosyl transferase in mononuclear leukocytes of patients with adenomatous polyps in the colon.
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma.
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.
Adenomatous Polyposis Coli
Absence of stimulation of poly(ADP-ribose) polymerase activity in patients predisposed to colon cancer.
Glial reactions and degeneration of myelinated processes in spinal cord gray matter in chronic experimental autoimmune encephalomyelitis.
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Adrenal Cortex Neoplasms
Bitter Melon (Momordica charantia) Extract Suppresses Adrenocortical Cancer Cell Proliferation Through Modulation of the Apoptotic Pathway, Steroidogenesis, and Insulin-Like Growth Factor Type 1 Receptor/RAC-? Serine/Threonine-Protein Kinase Signaling.
Adrenal Insufficiency
Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis.
Albuminuria
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Theobromine increases NAD?/Sirt-1 activity and protects the kidney under diabetic conditions.
Alveolar Bone Loss
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes.
Alzheimer Disease
Activation of PARP by oxidative stress induced by ?-amyloid: implications for Alzheimer's disease.
Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus.
Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death.
Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.
Cancer Imprints an Increased PARP-1 and p53-Dependent Resistance to Oxidative Stress on Lymphocytes of Patients That Later Develop Alzheimer's Disease.
Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease.
In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease.
Inhibition of poly(ADP-ribose) polymerase-1 alters expression of mitochondria-related genes in PC12 cells: relevance to mitochondrial homeostasis in neurodegenerative disorders.
Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk.
Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A?(1-42)-induced rat model of Alzheimer's disease.
Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition.
Papers of note in Science Translational Medicine 9 (392).
PARP1 gene variation and microglial activity on [(11)C]PBR28 PET in older adults at risk for Alzheimer's disease.
Poly(ADP-ribose) Polymerase-1 in Amyloid Beta Toxicity and Alzheimer's Disease.
PolyADP-ribosylation is involved in neurotrophic activity.
Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study.
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Transient OGG1, APE1, PARP1 and Pol? expression in an Alzheimer's disease mouse model.
Variants of Base Excision Repair Genes MUTYH , PARP1 and XRCC1 in Alzheimer's Disease Risk.
Amnesia
Inhibition of PARP-1 participates in the mechanisms of propofol-induced amnesia in mice and human.
Amyotrophic Lateral Sclerosis
Low levels of selenium compounds are selectively toxic for a human neuron cell line through ROS/RNS increase and apoptotic process activation.
PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients.
Reactive astrocytes express PARP in the central nervous system of SOD(G93A) transgenic mice.
Anemia
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Aneurysm
Clinical perspectives of PARP inhibitors.
Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Angina, Unstable
Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina.
Angiomyolipoma
Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Anthrax
Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative.
Antiphospholipid Syndrome
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders.
Aortic Aneurysm, Abdominal
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice.
Aortic Valve Stenosis
Increased transcript level of poly(ADP-ribose) polymerase (PARP-1) in human tricuspid compared with bicuspid aortic valves correlates with the stenosis severity.
Arthritis
GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation.
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase.
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus.
Poly(ADP-ribose) polymerase inhibitors.
Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model.
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity.
Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase.
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Arthritis, Experimental
Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Arthritis, Rheumatoid
A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis.
Beyond dna repair,the immunological role of parp-1 and its siblings.
Lack of association between Poly(ADP-ribose) polymerase (PARP) polymorphisms and rheumatoid arthritis in a Korean population.
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts.
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1.
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Asbestosis
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Asthma
Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.
Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis.
Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma.
Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma.
Genomic Instability in Chronic Airway Inflammatory Diseases.
Increased poly(ADP-ribose) polymerase (PARP)-1 expression and activity are associated with inflammation but not goblet cell metaplasia in murine models of allergen-induced airway inflammation.
Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs.
Investigation of poly (ADP-ribose) polymerase-1 genetic variants as a possible risk for allergic rhinitis.
Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor ?B-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase.
PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.
PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function.
PARP-1: a new player in the asthma field?
Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Silencing of poly(ADP-ribose) polymerase-1 suppresses hyperstretch-induced expression of inflammatory cytokines in vitro.
The Ala allele at Val762Ala polymorphism in poly(ADP-ribose) polymerase-1 (PARP-1) gene is associated with a decreased risk of asthma in a Turkish population.
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Astrocytoma
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity.
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
PARP1 expression in pediatric central nervous system tumors.
Ataxia
p53 Activation by nitric oxide involves down-regulation of Mdm2.
The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.
Ataxia Telangiectasia
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Identification of proteins in the hamster DNA end-binding complex.
Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy.
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Introductory review: involvement of ADP-ribosylation in cellular recovery from some forms of DNA damage.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Monitoring and signaling of radiation-induced damage in mammalian cells.
Novel and emerging drugs for rarer chronic lymphoid leukaemias.
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Poly(ADP-ribose) polymerase activity is not affected in ataxia telangiectasia cells and knockout mice.
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Shelterin-Mediated Telomere Protection.
Targeted cancer therapies based on the inhibition of DNA strand break repair.
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis.
The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication.
The Herpesvirus Nuclear Egress Complex Component, UL31, Can Be Recruited to Sites of DNA Damage Through Poly-ADP Ribose Binding.
The inhibition of poly(ADP-ribose) polymerase enhances growth rates of ataxia telangiectasia cells.
Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer.
Atherosclerosis
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.
Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response.
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels.
PARP-1 Involvement in Autophagy and Their Roles in Apoptosis of Vascular Smooth Muscle Cells under Oxidative Stress.
PARP-1 Represses LXR-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages.
PARP1 is required for adhesion molecule expression in atherogenesis.
PJ34, a PARP1 inhibitor, promotes endothelial repair in a rabbit model of high fat diet-induced atherosclerosis.
Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction.
Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia.
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications.
Poly(ADP-ribose) polymerase 1 deficiency increases nitric oxide production and attenuates aortic atherogenesis through downregulation of arginase II.
Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Poly(ADP-ribose) polymerase 1 inhibition protects human aortic endothelial cells against LPS-induced inflammation response.
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content.
Atrial Fibrillation
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation.
Autoimmune Diseases
Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin.
Autoantibodies to Poly(ADP-Ribose) Polymerase in Centenarians: A Reappraisal of Grabar's Hypothesis.
PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus.
Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
The Role of PARP-1 in Host-Pathogen Interaction and Cellular Stress Responses.
Transcriptional reprogramming and resistance to colonic mucosal injury in Poly(ADP-ribose) polymerase 1 (PARP1)-deficient mice.
Azoospermia
An ADP-ribosyltransferase 3 (ART3) variant is associated with reduced sperm counts in Czech males: case/control association study replicating results from the Japanese population.
Association of polymorphisms in ART3 gene with male infertility in the Chinese population.
Bacterial Infections
Host poly(ADP-ribose) polymerases (PARPs) in acute and chronic bacterial infections.
Barrett Esophagus
Dysregulation of PARP1 is involved in development of Barrett's esophagus.
MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
Blister
Activation of poly [ADP-Ribose] polymerase in endothelial cells and keratinocytes: role in an in vitro model of sulfur mustard-mediated vesication.
Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells.
Neolignans from Nectandra megapotamica (Lauraceae) Display in vitro Cytotoxic Activity and Induce Apoptosis in Leukemia Cells.
PARP determines the mode of cell death in skin fibroblasts, but not keratinocytes, exposed to sulfur mustard.
Putative role of proteolysis and inflammatory response in the toxicity of nerve and blister chemical warfare agents: implications for multi-threat medical countermeasures.
Bloom Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Bone Diseases
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Bone Neoplasms
Spinal RhoA/Rho Kinase Signaling Pathway may Participate in the Development of Bone Cancer Pain.
Bone Resorption
Rho-A is critical for osteoclast podosome organization, motility, and bone resorption.
Role of the activation of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis.
The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts.
Brain Death
Activation and modulation of cardiac poly-adenosine diphosphate ribose polymerase activity in a rat model of brain death.
Brain Diseases
Apoptosis and microglial activation in influenza encephalopathy.
PARP inhibition delays progression of mitochondrial encephalopathy in mice.
Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Brain Edema
Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats.
Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death.
Brain Infarction
Neuronal death in brain infarcts in man.
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage.
Brain Injuries
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study.
Acute Meningitis.
At the scene of ischemic brain injury: is PARP a perp?
Biphasic changes in the levels of poly(ADP-ribose) polymerase-1 and caspase 3 in the immature brain following hypoxia-ischemia.
Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2.
Drug-induced hypothermia begun 5 minutes after injury with a poly(adenosine 5'-diphosphate-ribose) polymerase inhibitor reduces hypoxic brain injury in rat pups.
Effects of Poly(ADP-Ribose) Polymerase-1 Inhibition in a Neonatal Rodent Model of Hypoxic-Ischemic Injury.
Effects of transient global ischemia and kainate on poly(ADP-ribose) polymerase (PARP) gene expression and proteolytic cleavage in gerbil and rat brains.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Hyperglycemia potentiates a shift from apoptosis to RIP1-dependent necroptosis.
Influence of PARP-1 polymorphisms in patients after traumatic brain injury.
Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide.
Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.
Microglial activation induced by the alarmin S100B is regulated by poly(ADP-ribose) polymerase-1.
NAD+ and NADH in ischemic brain injury.
NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases.
Neuroprotective effects of a novel Poly (ADP-Ribose) Polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons.
Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Oxidative Stress and NAD(+) in Ischemic Brain Injury: Current Advances and Future Perspectives.
Oxidative stress in bacterial meningitis.
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury.
Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice.
Poly(ADP-ribose) polymerase-1 and its clinical applications in brain injury.
Poly(ADP-ribosyl)ation and stroke.
Postnatal Age Influences Hypoglycemia-induced Poly(ADP-ribose) Polymerase-1 Activation in the Brain Regions of Rats.
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Roles of NAD (+) , PARP-1, and Sirtuins in Cell Death, Ischemic Brain Injury, and Synchrotron Radiation X-Ray-Induced Tissue Injury.
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke.
Temporal patterns of poly(ADP-ribose) polymerase activation in the cortex following experimental brain injury in the rat.
[Involvement of caspase on apoptosis in ischemia-induced neuronal cell death: usefulness of caspase inhibitors for stroke therapy]
Brain Injuries, Traumatic
A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma.
Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat.
Effect of Acute Poly(ADP-Ribose) Polymerase Inhibition by 3-AB on Blood-Brain Barrier Permeability and Edema Formation After Focal Traumatic Brain Injury in Rats.
Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury.
Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection.
Influence of PARP-1 polymorphisms in patients after traumatic brain injury.
Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide.
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor.
PARP inhibition improves the effectiveness of neural stem cell transplantation in experimental brain trauma.
PARP-1 Inhibition Attenuates Neuronal Loss, Microglia Activation and Neurological Deficits after Traumatic Brain Injury.
Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats.
Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain.
Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca(2+) Permeable ?-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice.
Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-?B in a mouse model of TBI.
Protective functions of PJ34, a PARP inhibitor, is related to down-regulation of calpain and NF-?B in a mouse model of TBI.
Reduction of cognitive and motor deficits after traumatic brain injury in mice deficient in poly(ADP-ribose) polymerase.
The expression pattern of ADP-ribosyltransferase 3 in rat traumatic brain injury.
Traumatic brain injury in mice deficient in poly-ADP(ribose) polymerase: a preliminary report.
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Brain Ischemia
3-Aminobenzamide reduces brain infarction and neutrophil infiltration after transient focal cerebral ischemia in mice.
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Another "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?
Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice.
Apoptosis-inducing factor triggered by poly(ADP-Ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia.
Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.
Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair.
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors.
Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia.
Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats.
Differential PARP Cleavage: An Indication of Heterogeneous Forms of Cell Death and Involvement of Multiple Proteases in the Infarct of Focal Cerebral Ischemia in Rat.
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain.
Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-?B nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
Inhibition of poly (ADP-ribose) polymerase and caspase-3, but not caspase-1, prevents apoptosis and improves spatial memory of rats with twice-repeated cerebral ischemia.
Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation.
Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection.
Mitochondrial impairment induced by poly(ADP-ribose) polymerase-1 activation in cortical neurons after oxygen and glucose deprivation.
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1.
Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.
Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia.
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Neuroprotective effects of poly (ADP-ribose) polymerase inhibitors in transient focal cerebral ischemia of rats.
Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia.
NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase.
Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia.
Oxidative Stress and NAD(+) in Ischemic Brain Injury: Current Advances and Future Perspectives.
Oxidative stress in brain ischemia.
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.
Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway--do androgens matter?
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.
Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke.
Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.
Poly(ADP-Ribose)-Polymerase-Catalyzed Hydrolysis of NAD(+): QM/MM Simulation of the Enzyme Reaction.
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
Poly(ADP-ribosyl)ation and stroke.
Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia.
Protection of the brain following cerebral ischemia through the attenuation of PARP-1-induced neurovascular unit damage in rats.
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
Role of continuous high thoracic epidural anesthesia in hippocampal apoptosis after global cerebral ischemia in rats.
Role of superoxide in poly(ADP-ribose) polymerase upregulation after transient cerebral ischemia.
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke.
SPATIAL AND FUNCTIONAL RELATIONSHIP BETWEEN POLY(ADP-RIBOSE) POLYMERASE-1 AND POLY(ADP-RIBOSE) GLYCOHYDROLASE IN THE BRAIN.
The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase.
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors.
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Brain Neoplasms
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors.
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Chemopotentiation by PARP inhibitors in cancer therapy.
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice.
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors.
The potential role and application of PARP inhibitors in cancer treatment.
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Breast Diseases
Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis.
Breast Neoplasms
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression.
2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation.
3-Aminobenzamide delays rejoining of DNA strand breaks in gamma-irradiated lymphocytes from patients with breast cancer and not cervical cancer.
4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells.
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
?-hydroxyundec-9-enoic acid induces apoptosis by ROS mediated JNK and p38 phosphorylation in breast cancer cell lines.
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.
A conserved NAD(+) binding pocket that regulates protein-protein interactions during aging.
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer.
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
A population-based study of the Arg399Gln polymorphism in X-ray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
A review of triple-negative breast cancer.
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Adenovirus-mediated p53 and ING4 gene co?transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
Advances in PARP inhibitors for the treatment of breast cancer.
Advances in the use of PARP inhibitor therapy for breast cancer.
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Airborne particulate collected from central Taiwan induces DNA strand breaks, Poly(ADP-ribose) polymerase-1 activation, and estrogen-disrupting activity in human breast carcinoma cell lines.
An HTS-compatible HTRF assay measuring the glycohydrolase activity of human PARG.
An update on PARP inhibitors--moving to the adjuvant setting.
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Androgen receptor inhibitor enhances the anti-tumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response.
Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.
Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo.
Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7).
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ER? and HER2/neu.
ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways.
Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population.
Association of PARP1 rs4653734, rs907187 and rs1136410 variants with breast cancer risk among Iranian women.
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines.
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death.
Biological and clinical significance of PARP1 protein expression in breast cancer.
BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium.
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.
Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
BRCA mutation testing in determining breast cancer therapy.
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
BRCA1/2 testing: therapeutic implications for breast cancer management.
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
BRCAness: a deeper insight into basal-like breast tumors.
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699).
Breast cancer under age 40: a different approach.
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway.
Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative.
Catalase Abrogates ?-Lapachone-Induced PARP1 Hyperactivation-Directed Programmed Necrosis in NQO1-Positive Breast Cancers.
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Caught in the act: binding of Ku and PARP to MARs reveals novel aspects of their functional interaction.
CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells.
Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819.
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy.
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Correction: Association between PARP-1 V762A Polymorphism and Breast Cancer Susceptibility in Saudi Population.
Correction: HP1? is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells.
Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757].
Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells.
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway.
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Data on the effects of anti-cancer drug of resveratrol in breast cancer cells, MDA-MB-231 cells.
Decreased DNA repair gene XRCC1 expression is associated with radiotherapy-induced acute side effects in breast cancer patients.
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition.
Deoxyrhapontigenin, a Natural Stilbene Derivative Isolated From Rheum undulatum L. Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Breast Cancer Cells.
Detection of heterogeneity of apoptotic fragments of poly (ADP-ribose) polymerase in MDA-MB-468 breast cancer cells: two-dimensional gel analysis.
Detection of PARP-1 activity based on hyperbranched-poly (ADP-ribose) polymers responsive current in artificial nanochannels.
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
Development of PARP inhibitors in gynecological malignancies.
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Disparity in the induction of glutathione depletion, ROS formation, poly(ADP-ribose) polymerase-1 activation, and apoptosis by quinonoid derivatives of naphthalene in human cultured cells.
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
DNA damage repair in breast cancer and its therapeutic implications.
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs.
Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Effects of passive smoking on breast cancer risk in pre/post-menopausal women as modified by polymorphisms of PARP1 and ESR1.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Emerging PARP inhibitors for treating breast cancer.
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Enhancement of chemotherapeutically-induced apoptosis in vivo by biochemical modulation of poly (ADP-ribose) polymerase.
Enhancing radiosensitivity: targeting the DNA repair pathways.
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Erratum to "Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness" [Neoplasia 16 (2014) 43-72].
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Evidence to date: talazoparib in the treatment of breast cancer.
Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
First PARP Inhibitor Ok'd for Breast Cancer.
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Functional profiling of nucleotide Excision repair in breast cancer.
Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family.
Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231.
GALNT6 Promotes Tumorigenicity and Metastasis of Breast Cancer Cell via ?-catenin/MUC1-C Signaling Pathway.
Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells.
gammaH2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids.
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression.
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer.
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.
Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells.
Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells.
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair.
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.
Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
HP1? Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy.
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes.
Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.
In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.
In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab?paclitaxel on triple?negative and luminal A breast cancer cells.
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047.
Induction of cytotoxicity, aldehydic DNA lesions, and poly(ADP-ribose) polymerase-1 activation by catechol derivatives of pentachlorophenol in calf thymus DNA and in human breast cancer cells.
Induction of ROS formation, poly(ADP-ribose) polymerase-1 activation, and cell death by PCB126 and PCB153 in human T47D and MDA-MB-231 breast cancer cells.
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.
Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine.
Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Inhibition of TACC3 by a small molecule inhibitor in breast cancer.
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.
Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse.
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage.
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Isoalantolactone induces apoptosis in human breast cancer cells via ROS-mediated mitochondrial pathway and downregulation of SIRT1.
JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks.
KIFC1 is a novel potential therapeutic target for breast cancer.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.
Mechanisms of PARP inhibitor sensitivity and resistance.
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA.
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
Methoxyphenylcipro induces antitumor activity in human cancer cells.
Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
MGMT Inhibition Restores ER? Functional Sensitivity to Anti-Estrogen Therapy.
MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Molecular Testing in Breast Cancer.
More breast cancer patients could benefit from PARP inhibitors.
Mutant p53 mediates survival of breast cancer cells.
Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer.
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Niraparib for the treatment of ovarian cancer.
Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells.
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node?negative early breast cancer: 15-year follow-up.
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Olaparib for the treatment of breast cancer.
Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Olaparib Keeps Hereditary Breast Tumors in Check.
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.
Oxidative stress, DNA repair, and cancer susceptibility.
p110? and p110? isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells.
p38? mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
PARP inhibition in breast cancer.
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
PARP inhibitor development for systemic cancer targeting.
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
PARP inhibitor treatment in ovarian and breast cancer.
PARP inhibitors and more.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP inhibitors and their evolving role in breast cancer.
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
PARP Inhibitors in Breast Cancer.
PARP inhibitors in breast cancer: BRCA and beyond.
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
PARP Inhibitors in Breast Cancer: Why, How, and When?
PARP inhibitors in cancer therapy: promise, progress, and puzzles.
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
PARP inhibitors in the management of breast cancer: current data and future prospects.
PARP inhibitors stumble in breast cancer.
PARP inhibitors--current status and the walk towards early breast cancer.
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
PARP1 Inhibitors: antitumor drug design.
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
PARP3 controls TGF? and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Period-2: a tumor suppressor gene in breast cancer.
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
Poly (ADP-ribose) polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality.
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences.
Poly(ADP-ribose) polymerase as a novel regulator of 17?-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer.
Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis.
Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer.
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Poly(ADP-ribose) polymerase-1 promotes recruitment of meiotic recombination-11 to chromatin and DNA double-strand break repair in Ku70-deficient breast cancer cells.
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.
Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women: a case control analysis.
PPAR?-inactive ?2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis.
Prosopis juliflora (Sw.), DC induces apoptosis and cell cycle arrest in triple negative breast cancer cells: in vitro and in vivo investigations.
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Rare mutations in XRCC2 increase the risk of breast cancer.
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Recent developments in treatment stratification for metastatic breast cancer.
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Resurrection of PARP Inhibitors in Breast Cancer.
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway.
Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation.
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment.
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation.
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Sustained Cytotoxicity of Wogonin on Breast Cancer Cells by Encapsulation in Solid Lipid Nanoparticles.
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Synthesis, cytotoxic evaluation and molecular docking study of novel quinazoline derivatives as PARP-1 inhibitors.
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.
Tanshinone IIA Induces Mitochondria Dependent Apoptosis in Prostate Cancer Cells in Association with an Inhibition of Phosphoinositide 3-Kinase/AKT Pathway.
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
Targeted therapy in breast cancer: what's new?
Targeted therapy of metastatic breast cancer.
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Targeting DNA repair in breast cancer.
Targeting DNA repair in breast cancer: A clinical and translational update.
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
The C Allele of a Synonymous SNP (rs1805414, Ala284Ala) in PARP1 is a Risk Factor for Susceptibility to Breast Cancer in Saudi Patients.
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
The OlympiAD trial: who won the gold?
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
The potential of PARP inhibitors in genetic breast and ovarian cancers.
The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality.
The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells.
The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
The synthetic ?-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
The tumor invasion inhibitor dihydromotuporamine C activates RHO, remodels stress fibers and focal adhesions, and stimulates sodium-proton exchange.
Therapeutic innovations in breast cancer.
Therapeutic potential of PARP inhibitors for metastatic breast cancer.
TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage.
Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity.
Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23.
Translational highlights in breast cancer research and treatment: recent developments with clinical impact.
Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition.
Treating breast cancer in the 21st century: emerging biological therapies.
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Triptolide sensitizes human breast cancer cells to tumor necrosis factor???induced apoptosis by inhibiting activation of the nuclear factor??B pathway.
Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo.
Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis.
Update on PARP Inhibitors in Breast Cancer.
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.
Verrucarin A alters cell-cycle regulatory proteins and induces apoptosis through reactive oxygen species-dependent p38MAPK activation in the human breast cancer cell line MCF-7.
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
[18F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity.
[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
[Hereditary Breast and Ovarian Cancer Syndrome].
[New targeted therapies in breast cancer].
[Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
[On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
[PARP inhibitors and breast cancer: update and perspectives].
[PARP inhibitors--theoretical basis and clinical application].
[The Role of Preoperative Chemotherapy Depending on Breast Cancer Subtype].
Burkitt Lymphoma
Biological Effects of MC2050, a Quinazoline-Based PARP-1 Inhibitor, in Human Neuroblastoma and EBV-Positive Burkitt's Lymphoma Cells.
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.
Prolongation of the p53 response to DNA strand breaks in cells depleted of PARP by antisense RNA expression.
Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma.
Carcinogenesis
Advanced small cell lung cancer (SCLC): new challenges and new expectations.
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.
Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(-/-) fibroblasts after mitotic spindle disruption.
Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice.
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.
Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats.
Ex vivo study of MAPK profiles correlated with parameters of apoptosis during cervical carcinogenesis.
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Expression of the Gene Encoding Poly(ADP-ribose) Polymerase-1 Is Modulated by Fibronectin during Corneal Wound Healing.
Functional Characterization of Long Noncoding RNA Lnc_bc060912 in Human Lung Carcinoma Cells.
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death.
Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors.
Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis.
H2AX a promising biomarker for lung cancer: a review.
Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs.
Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity.
Inhibition of methylazoxymethanol acetate initiation of colon carcinogenesis in rats by treatment with the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide.
Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Inhibition of poly(ADP-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice.
Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
Interaction among susceptibility genotypes of PARP1 SNPs in thyroid carcinoma.
Involvement of poly(ADP-ribose) polymerase in trophoblastic cell differentiation during tumorigenesis.
Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells.
Loss of PIDD limits NF-?B activation and cytokine production but not cell survival or transformation after DNA damage.
Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice.
Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation.
Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.
Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges.
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo.
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
PARP-1 activity in normal and cancerous human endometrium and its relationship with quantity of abasic sites (AP).
Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice.
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer.
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.
PARP-1-dependent 3-nitrotyrosine protein modification after DNA damage.
PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress.
PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.
Poly(ADP-ribose) polymerase gene on chromosome 1q: early role in differentiation linked replication; gene on human chromosome 13q: marker of carcinogenesis.
Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis.
Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Poly(ADP-ribosyl)ation and aging.
PolyADP-ribosylation and cancer.
Possible role of poly(ADP-ribose) polymerase on the early stage of liver carcinogenesis by diethylnitrosamine in rats.
RecQ helicases and PARP1 team up in maintaining genome integrity.
Regulation of the poly(ADP-ribose) polymerase-1 gene expression by the transcription factors Sp1 and Sp3 is under the influence of cell density in primary cultured cells.
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Tannins elevate the level of poly(ADP-ribose) in HeLa cell extracts.
The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis.
The emerging role of poly(ADP-ribose) polymerase-1 in longevity.
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis.
The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression.
Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Transcript response of soft coral (Scleronephthya gracillimum) on exposure to polycyclic aromatic hydrocarbons.
Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
[Diethylnitrosamine-induced carcinogenesis in PARP-1(-/-) and PARP-1(+/+) mice]
[DNA damage in human peripheral blood lymphocyte caused by nickel and cadmium]
[Features of carcinogenesis and aging in knockout male mice PARP-1]
[Poly(ADP-ribosa)polymerase--the relationships with life span and carcinogenesis]
Carcinoid Tumor
MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype.
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
Carcinoma
-
A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma.
Antimicrobial cyclic decapeptides with anticancer activity.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma.
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population.
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins ?v?3 and ?v?5.
c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-{beta}-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Characterization of MVP and VPARP assembly into vault ribonucleoprotein complexes.
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Comparative evaluation of antiproliferative, antiangiogenic and apoptosis inducing potential of black tea polyphenols in the hamster buccal pouch carcinogenesis model.
Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Design, synthesis, and anticancer evaluation of long-chain alkoxylated mono-carbonyl analogues of curcumin.
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity.
Discovery and Structure-Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG).
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.
Effect of Poly (ADP-ribose) Polymerase-1 Inhibition on the Proliferation of Murine Colon Carcinoma CT26 Cells.
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas.
Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.
Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein.
Flavone inhibition of tumor growth via apoptosis in vitro and in vivo.
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.
Identification of miRNA modulators to PARP inhibitor response.
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines.
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Levels of superoxide dismutases, glutathione, and poly(ADP-ribose) polymerase in radioresistant human KB carcinoma cell line.
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly(ADP-ribose) polymerase activity.
MBP-1 mediated apoptosis involves cytochrome c release from mitochondria.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF??B in tumour metastases of colon carcinoma.
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
PARP inhibitors: A new era of targeted therapy.
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma.
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent.
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Poly(ADP-ribose) polymerase activity in proliferating and quiescent murine mammary carcinoma cells.
Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells.
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation.
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
Prevention of oxidant-induced cell death in Caco-2 colon carcinoma cells after inhibition of poly(ADP-ribose) polymerase and Ca2+ chelation: involvement of a common mechanism.
Radiation-inducible Immunotherapy for Cancer: Senescent Tumor Cells as a Cancer Vaccine.
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Ras(V12) induces Survivin/AuroraB pathway conferring tumor cell apoptosis resistance.
Reversion of malignant phenotype by 5-iodo-6-amino-1,2-benzopyrone a non-covalently binding ligand of poly(ADP-ribose) polymerase.
RIG-I enhanced interferon independent apoptosis upon Junin virus infection.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK.
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells.
Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1.
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
Systemic treatment for hereditary cancers: a 2012 update.
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.
Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.
The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas.
The TLR7/8/9 antagonist IMO-8503 inhibits cancer-induced cachexia.
Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells.
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Valproate augments Niraparib killing of tumor cells.
Xanthorrhizol Induces Apoptosis Through ROS-Mediated MAPK Activation in Human Oral Squamous Cell Carcinoma Cells and Inhibits DMBA-Induced Oral Carcinogenesis in Hamsters.
[BRCA1 and BRCA2 - pathologists starting kit].
[Hereditary breast and ovarian cancers].
[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.]
[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]
[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
[The effect of tanshinone ?A potentiates the effects of Cisplatin in Fadu cells in vitro through downregulation of survivin].
Carcinoma, Acinar Cell
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Carcinoma, Basal Cell
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Carcinoma, Ductal
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Carcinoma, Ehrlich Tumor
NAD[S], an NAD analogue with reduced susceptibility to phosphodiesterase. Chemical synthesis and enzymic properties.
Poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells. Properties of the purified polymerase.
Purification of poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells by chromatography on DNA-agarose.
Carcinoma, Embryonal
PARP expression in germ cell tumours.
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Carcinoma, Endometrioid
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Carcinoma, Hepatocellular
2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation.
6,(5H)-phenanthridinone protects against carbon tetrachloride-induced cytotoxicity in human HepG2 cells.
Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells.
Autophagy suppresses radiation damage by activating PARP-1 and attenuating reactive oxygen species in hepatoma cells.
Chemopreventive action of Lygodium flexuosum extract in human hepatoma PLC/PRF/5 and Hep 3B cells.
Cloning and expression of cDNA for human poly(ADP-ribose) polymerase.
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Enhancement of cell permeabilization apoptosis-inducing activity of selenium nanoparticles by ATP surface decoration.
Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance.
Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation.
Identification of poly(ADP-ribose) polymerase-1 as a cell cycle regulator through modulating Sp1 mediated transcription in human hepatoma cells.
Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line.
Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation.
Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro.
Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.
Isolation of 4,4'-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma.
Macrophage mediated anti-proliferation effects of Anthodia camphorata non-polysaccharide based extracts on human hepatoma cells.
Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway.
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.
MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells.
Momordin Ic induces HepG2 cell apoptosis through MAPK and PI3K/Akt-mediated mitochondrial pathways.
NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma.
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization.
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
PARP10 suppresses tumor metastasis through regulation of Aurora A activity.
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Poly (ADP-ribose) polymerase inhibition synergizes with the NF-?B inhibitor DHMEQ to kill hepatocellular carcinoma cells.
Poly(ADP-ribose) synthase is the major endogenous nonhistone acceptor for poly(ADP-ribose) in alkylated rat hepatoma cells.
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.
Retraction Note: MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
The assessment of an in-vitro model for evaluating the role of PARP in ethanol-mediated hepatotoxicity.
The long noncoding RNA lncPARP1 contributes to progression of hepatocellular carcinoma through up-regulation of PARP1.
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.
Update on hepatocellular carcinoma breakthroughs: Poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy.
[Role of proteins in Fas-mediated apoptosis in tumor cells and lymphocytes co-cultured in vitro]
Carcinoma, Intraductal, Noninfiltrating
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Carcinoma, Lewis Lung
The TLR7/8/9 antagonist IMO-8503 inhibits cancer-induced cachexia.
Carcinoma, Merkel Cell
Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Carcinoma, Non-Small-Cell Lung
?-Hydroxyundec-9-enoic acid induces apoptosis through ROS-mediated endoplasmic reticulum stress in non-small cell lung cancer cells.
An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules.
Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
Pelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell lines.
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Replication-dependent ?-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.
Tankyrase 2 (TNKS2) polymorphism associated with risk in developing non-small cell lung cancer in a Chinese population.
Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
WITHDRAWN: An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
PARP inhibitors in epithelial ovarian cancer.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Targeted therapy of ovarian cancer including immune check point inhibitor.
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
The circuitous path of PARP inhibitor development in epithelial ovarian cancer.
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Treatment of recurrent ovarian cancer.
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
[Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Carcinoma, Renal Cell
Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.
Carcinoma, Squamous Cell
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population.
Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Discovery and Structure-Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG).
Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.
PARP inhibitors: A new era of targeted therapy.
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma.
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma.
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Xanthorrhizol Induces Apoptosis Through ROS-Mediated MAPK Activation in Human Oral Squamous Cell Carcinoma Cells and Inhibits DMBA-Induced Oral Carcinogenesis in Hamsters.
[The effect of tanshinone ?A potentiates the effects of Cisplatin in Fadu cells in vitro through downregulation of survivin].
Carcinoma, Transitional Cell
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.
Cardiomegaly
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
PARP mediates structural alterations in diabetic cardiomyopathy.
PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.
PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.
PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.
Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy.
Salvianolic acid B protects cardiomyocytes from angiotensin II-induced hypertrophy via inhibition of PARP-1.
The orphan receptor NOR1 participates in isoproterenol-induced cardiac hypertrophy by regulating PARP-1.
The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy.
Transcriptome-Wide Analysis Identifies Novel Associations With Blood Pressure.
Cardiomyopathies
A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways.
Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Disruption of Nrf2 Synergizes with High Glucose to Cause Heightened Myocardial Oxidative Stress and Severe Cardiomyopathy in Diabetic Mice.
Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption.
PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1? axis.
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Cardiomyopathy, Dilated
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
Cardiotoxicity
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Hesperidin promotes lysosomal biogenesis in chronically ethanol-induced cardiotoxicity in rats: A proposed mechanisms of protection.
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats.
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Cardiovascular Diseases
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1.
Novel modulators of poly(ADP-ribose) polymerase.
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.
PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription.
PCB-induced endothelial cell dysfunction: role of poly(ADP-ribose) polymerase.
Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase.
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
caspase-3 deficiency
Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death.
Cataract
Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract in a Chinese Han population: A two-stage case-control analysis.
PARP-1 inhibition influences the oxidative stress response of the human lens.
Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats.
Central Nervous System Diseases
Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Targeting poly(ADP-ribose)polymerase1 in neurological diseases: A promising trove for new pharmacological interventions to enter clinical translation.
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Central Nervous System Neoplasms
PARP1 expression in pediatric central nervous system tumors.
Cerebellar Ataxia
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.
Cerebral Hemorrhage
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats.
Cerebral Infarction
Evaluation of the poly(ADP-ribose) polymerase gene in human stroke.
MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.
Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Protection of the brain following cerebral ischemia through the attenuation of PARP-1-induced neurovascular unit damage in rats.
Reversible induction of PARP1 degradation by p53-inducible cis-imidazoline compounds.
Cerebrovascular Disorders
Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.
Cervical Intraepithelial Neoplasia
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Chagas Disease
Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.
PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance.
Cholangiocarcinoma
Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines.
Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression.
PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells.
Cholera
ADP-ribosyltransferase-specific modification of human neutrophil peptide-1.
DeoxyNAD and deoxyADP-ribosylation of proteins.
Human glycolipid transfer protein (GLTP) expression modulates cell shape.
Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells.
Mono(adenosine diphosphate ribosyl) transferase in Xenopus tissues. Direct demonstration by a zymographic localization in sodium dodecyl sulfate--polyacrylamide gels.
TLR2 transmodulates monocyte adhesion and transmigration via Rac1- and PI3K-mediated inside-out signaling in response to Porphyromonas gingivalis fimbriae.
Chondrosarcoma
BL-038, a Benzofuran Derivative, Induces Cell Apoptosis in Human Chondrosarcoma Cells through Reactive Oxygen Species/Mitochondrial Dysfunction and the Caspases Dependent Pathway.
Current questions in bone sarcomas.
Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation.
Vacuolar Protein Sorting 4B (VPS4B) Regulates Apoptosis of Chondrocytes via p38 Mitogen-Activated Protein Kinases (MAPK) in Osteoarthritis.
Chordoma
Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma.
Combination of PARP inhibitor and temozolomide to suppress chordoma progression.
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis.
Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Choriocarcinoma
Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome.
PARP expression in germ cell tumours.
Cockayne Syndrome
Cockayne syndrome group A and B proteins converge on transcription-linked resolution of non-B DNA.
Cooperation of the Cockayne syndrome group B protein and poly(ADP-ribose) polymerase 1 in the response to oxidative stress.
Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice.
Linking DNA damage, NAD(+)/SIRT1, and aging.
PARP and CSB modulate the processing of transcription-mediated DNA strand breaks.
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Poly(ADP-ribose) polymerase 1 (PARP1) promotes oxidative stress-induced association of Cockayne syndrome group B protein with chromatin.
Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein.
Coinfection
Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses.
C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Colitis
5-Aminoisoquinolinone reduces colon injury by experimental colitis.
Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis.
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Beyond dna repair,the immunological role of parp-1 and its siblings.
Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein.
GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat.
Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis.
Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis.
PARP inhibition reduces acute colonic inflammation in rats.
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Poly(ADP-ribose) polymerase inhibitors.
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation.
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
The Peri-appendiceal Red Patch in Ulcerative Colitis: Review of the University of Chicago Experience.
Transcriptional reprogramming and resistance to colonic mucosal injury in Poly(ADP-ribose) polymerase 1 (PARP1)-deficient mice.
Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock.
Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB.
Colitis, Ulcerative
PARP inhibition reduces acute colonic inflammation in rats.
Colonic Neoplasms
2'-Hydroxycinnamaldehyde induces apoptosis through HSF1-mediated BAG3 expression.
8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients.
?-Lapachone Inhibits Lung Metastasis of Colorectal Cancer by Inducing Apoptosis of CT26 Cells.
Absence of stimulation of poly(ADP-ribose) polymerase activity in patients predisposed to colon cancer.
Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.
Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells.
Anticancer effect of fermented Insampaedok-san in human colon cancer cells: a pilot study.
Apigenin induces apoptosis by suppressing Bcl-xl and Mcl-1 simultaneously via signal transducer and activator of transcription 3 signaling in colon cancer.
Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation.
Capsaicin Mediates Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells via Stabilizing and Activating p53.
CD44-shRNA recombinant adenovirus inhibits cell proliferation, invasion, and migration, and promotes apoptosis in HCT116 colon cancer cells.
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819.
Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol.
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.
Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis.
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Dimeric 3,5-bis(benzylidene)-4-piperidones: A novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest through the caspase-3 and PARP pathways.
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Functional characterization of peroxisome proliferator-activated receptor-?/? expression in colon cancer.
Human colon cancer HT-29 cell death responses to doxorubicin and Morus Alba leaves flavonoid extract.
Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways.
Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway.
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization.
Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways.
Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Patulin induces colorectal cancer cells apoptosis through EGR-1 dependent ATF3 up-regulation.
Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway.
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.
Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study.
Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice.
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Terpenes from essential oils and hydrolate of Teucrium alopecurus triggered apoptotic events dependent on caspases activation and PARP cleavage in human colon cancer cells through decreased protein expressions.
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
The pro-apoptotic effect of quercetin in cancer cell lines requires ER?-dependent signals.
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death.
Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells.
Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups.
Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells.
Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells.
Colorectal Neoplasms
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Colorectal cancers differ in respect of PARP-1 protein expression.
Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and ?-H2AX foci formation in colorectal cancer.
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Effect of acidic environment and p53 on apoptosis induction by hyperthermia.
Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
HOXD8 exerts a tumor-suppressing role in colorectal cancer as an apoptotic inducer.
Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer.
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells.
Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions.
MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer.
MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.
MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers.
MSH3 Mediates Sensitization of Colorectal Cancer Cells to Cisplatin, Oxaliplatin, and a Poly(ADP-ribose) Polymerase Inhibitor.
New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells.
Nogo-B (Reticulon-4B) functions as a negative regulator of the apoptotic pathway through the interaction with c-FLIP in colorectal cancer cells.
Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration.
Novel mutations of the PARP-1 gene associated with colorectal cancer in the Saudi population.
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development.
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells.
Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a Northeast Chinese population.
Quantitative Proteomics Identifies DNA Repair as a Novel Biological Function for Hepatocyte Nuclear Factor 4? in Colorectal Cancer Cells.
Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate.
Reactive Oxygen Species and p53 Mediated Activation of p38 and Caspases is Critically Involved in Kaempferol Induced Apoptosis in Colorectal Cancer Cells.
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Temozolomide: Mechanisms of Action, Repair and Resistance.
The depletion of securin enhances butein-induced apoptosis and tumor inhibition in human colorectal cancer.
The Effect of Poly(ADP-ribose) Polymerase-1 Gene 3'Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort.
The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.
Ursolic Acid Induces Apoptosis in Colorectal Cancer Cells Partially via Upregulation of MicroRNA-4500 and Inhibition of JAK2/STAT3 Phosphorylation.
XRCC2 promotes colorectal cancer cell growth, regulates cell cycle progression, and apoptosis.
XRCC2 rs3218536 polymorphism decreases the sensitivity of colorectal cancer cells to poly(ADP-ribose) polymerase 1 inhibitor.
[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]
Colorectal Neoplasms, Hereditary Nonpolyposis
Temozolomide: Mechanisms of Action, Repair and Resistance.
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Congenital Abnormalities
Association of sperm morphology and the sperm deformity index (SDI) with poly (ADP-ribose) polymerase (PARP) cleavage inhibition.
Calcium Alleviates Fluoride-Induced Bone Damage by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction.
Coronary Artery Disease
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Coronary Occlusion
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Cough
Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling.
Cowpox
Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis.
IL-3 withdrawal activates a CrmA-insensitive poly(ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells.
Craniocerebral Trauma
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study.
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Poly(adenosine diphosphate-ribose) polymerase expression in human traumatic brain injury.
Crohn Disease
Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease.
Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn's disease.
Cryptorchidism
Heat stress reduces poly(ADPR)polymerase expression in rat testis.
Over expression of LDOC1 and PARP1, two pro-apoptotic genes, in a patient with cryptorchidism and DiGeorge anomaly.
Cystadenoma
Rapamycin-resistant PARP1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis (LAM).
Cystadenoma, Serous
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Cystic Fibrosis
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa.
Distinct fates of monocytes and T cells directly activated by Pseudomonas aeruginosa exoenzyme S.
Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines.
Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections.
Cystitis
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat.
Cysts
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
cytidine deaminase deficiency
Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity.
Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA.
Dehydration
Effects of long-term dehydration on oxidative stress, apoptotic markers and neuropeptides in the gastric mucosa of the dromedary camel.
Physiological, biochemical and molecular responses to water stress and rehydration in Mediterranean adapted tomato landraces.
Dementia
Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease.
Demyelinating Diseases
Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage.
IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis.
Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.
PARP-1 deletion promotes subventricular zone neural stem cells toward a glial fate.
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Dermatitis
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Dermatitis, Allergic Contact
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Dermatitis, Contact
Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress.
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity.
Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity.
Dermatitis, Phototoxic
The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Diabetes Complications
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation.
Does diabetes mellitus target motor neurons?
Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
Marrow-Derived Cells Regulate the Development of Early Diabetic Retinopathy and Tactile Allodynia in Mice.
Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications.
Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited.
PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes.
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
PARP mediates structural alterations in diabetic cardiomyopathy.
Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy.
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Poly(ADP-ribose) polymerase is involved in the development of diabetic cystopathy via regulation of nuclear factor kappa B.
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Diabetes Mellitus
Adenosine thiamine triphosphate (AThTP) inhibits poly(ADP-ribose) polymerase-1 (PARP-1) activity.
Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase.
Effects of Trans-Resveratrol on hyperglycemia-induced abnormal spermatogenesis, DNA damage and alterations in poly (ADP-ribose) polymerase signaling in rat testis.
Nitrative stress and poly(ADP-ribose) polymerase activation in healthy and gestational diabetic pregnancies.
PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.
Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus.
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Role of poly (ADP-ribose) polymerase-1 and cytokines in acute renal injury in elderly Chinese patients with diabetes mellitus.
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Theobromine increases NAD?/Sirt-1 activity and protects the kidney under diabetic conditions.
Diabetes Mellitus, Experimental
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
A dinucleotide repeat polymorphism at the poly(ADP-ribose) polymerase gene is not associated with predisposition to type 1 diabetes in French Caucasians.
A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase.
Effects of Trans-Resveratrol on hyperglycemia-induced abnormal spermatogenesis, DNA damage and alterations in poly (ADP-ribose) polymerase signaling in rat testis.
Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin.
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
Poly(Adenosine 5'-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy.
Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Unexpected sensitivity of nonobese diabetic mice with a disrupted poly(ADP-Ribose) polymerase-1 gene to streptozotocin-induced and spontaneous diabetes.
Diabetes Mellitus, Type 2
Enhanced NF?B Activity Impairs Vascular Function through PARP-1, SP-1 and COX2-Dependent Mechanisms in Type 2 Diabetes.
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes.
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity.
Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients.
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes.
The role of impaired insulin/IGF action in primary diabetic encephalopathy.
Diabetes, Gestational
[The severity of gestational diabetes mellitus affects microvascular dysfunction measured three years after pregnancy that may be related to increased oxidative stress].
Diabetic Cardiomyopathies
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme.
PARP mediates structural alterations in diabetic cardiomyopathy.
PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1? axis.
Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy.
Diabetic Nephropathies
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation.
Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP.
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.
Psoralea corylifolia L. Seed Extract Attenuates Diabetic Nephropathy by Inhibiting Renal Fibrosis and Apoptosis in Streptozotocin-Induced Diabetic Mice.
Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.
Diabetic Neuropathies
Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion.
Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats.
Emerging drugs for diabetic neuropathy.
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy.
Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients.
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets.
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-{alpha}
Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited.
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy.
Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy.
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
Treatment with Actovegin® Improves Sensory Nerve Function and Pathology in Streptozotocin-Diabetic Rats via Mechanisms Involving Inhibition of PARP Activation.
Diabetic Retinopathy
Aldose Reductase / Polyol Inhibitors For Diabetic Retinopathy.
Effect of the regimen of Gaoshan Hongjingtian on the mechanism of poly (ADP-ribose) polymerase regulation of nuclear factor kappa B in the experimental diabetic retinopathy.
Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes.
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB.
Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy.
Role of PARP-1 as a novel transcriptional regulator of MMP-9 in diabetic retinopathy.
The Poly(ADP-Ribose)Polymerase-1 Inhibitor 1,5-Isoquinolinediol Attenuate Diabetes-Induced NADPH Oxidase-Derived Oxidative Stress in Retina.
DiGeorge Syndrome
Over expression of LDOC1 and PARP1, two pro-apoptotic genes, in a patient with cryptorchidism and DiGeorge anomaly.
Diphtheria
A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly.
Assessment of Intracellular Auto-Modification Levels of ARTD10 Using Mono-ADP-Ribose-Specific Macrodomains 2 and 3 of Murine Artd8.
Bacterial toxins inhibiting or activating small GTP-binding proteins.
Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3.
PARP inhibitors: polypharmacology versus selective inhibition.
PARP-1 and gene regulation: Progress and puzzles.
Production of exoenzyme S by clinical isolates of Pseudomonas aeruginosa.
Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A.
Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function.
Structural Basis for Lack of ADP-Ribosyltransferase Activity in Poly(ADP-Ribose) Polymerase-13/Zinc Finger Antiviral Protein.
Structure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosa.
Use of biotinylated NAD to label and purify ADP-ribosylated proteins.
DNA Repair-Deficiency Disorders
A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome.
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
PARP inhibition: A promising therapeutic target in ovarian cancer.
Predictive biomarkers for cancer therapy with PARP inhibitors.
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition.
Down Syndrome
Differential expression of PARP1 mRNA in leucocytes of patients with down's syndrome.
Dyslexia
The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia.
Dyslipidemias
Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.
Ectropion
The Curcumin Analogs 2-Pyridyl Cyclohexanone Induce Apoptosis via Inhibition of the JAK2-STAT3 Pathway in Human Esophageal Squamous Cell Carcinoma Cells.
Ehrlichiosis
Specific processing of poly(ADP-ribose) polymerase, accompanied by activation of caspase-3 and elevation/reduction of ceramide/hydrogen peroxide levels, during induction of apoptosis in host HL-60 cells infected by the human granulocytic ehrlichiosis (HGE) agent.
Encephalitis
Damage and repair of DNA in HIV encephalitis.
Estrogen treatment following severe burn injury reduces brain inflammation and apoptotic signaling.
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Encephalomyelitis
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Beyond dna repair,the immunological role of parp-1 and its siblings.
Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Beyond dna repair,the immunological role of parp-1 and its siblings.
Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis.
Poly(ADP-ribose) polymerase inhibitors.
Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.
The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
Encephalomyelitis, Venezuelan Equine
Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication.
Endodermal Sinus Tumor
PARP expression in germ cell tumours.
Endometrial Hyperplasia
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
Endometrial Neoplasms
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer.
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Moving From Mutation to Actionability.
PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells.
Endometriosis
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Endotoxemia
Nicotinamide increases systemic vascular resistance in ovine endotoxemia.
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models.
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia.
Enterocolitis, Necrotizing
Poly(ADP-Ribose) Polymerase-1: A Novel Therapeutic Target in Necrotizing Enterocolitis.
Eosinophilia
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.
Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.
Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia.
Ependymoma
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Epilepsy
Cellular NAD depletion and decline of SIRT1 activity play critical roles in PARP-1-mediated acute epileptic neuronal death in vitro.
Poly(ADP-ribose) polymerase inhibition protects epileptic hippocampal neurons from apoptosis via suppressing Akt-mediated apoptosis-inducing factor translocation in vitro.
Erectile Dysfunction
Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury.
Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice.
Erythema
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Esophageal Neoplasms
Involvement of homologous recombination in the synergism between cisplatin and poly(ADP-ribose) polymerase inhibition.
Single?cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer.
The Synthetic ?-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways.
Esophageal Squamous Cell Carcinoma
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Exanthema
Association of apoptosis-related microsatellite polymorphisms on chromosome 1q in Taiwanese systemic lupus erythematosus patients.
Fanconi Anemia
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia.
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
DNA Repair Deficient Chinese Hamster Ovary Cells Exhibiting Differential Sensitivity to Charged Particle Radiation under Aerobic and Hypoxic Conditions.
No abnormalities in the NAD+ ADP-ribosyltransferase (polymerizing) gene of transformed cells from a Fanconi's anemia patient.
Rare mutations in XRCC2 increase the risk of breast cancer.
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
The cellular control enzyme polyADP ribosyl transferase is eliminated in cultured Fanconi anemia fibroblasts at confluency.
The Fanconi anemia cell line HSC536N is not sensitive to interferon-gamma and does not cleave PARP in response to FAS-mediated cell killing.
Fatty Liver
Hepatocyte-Specific Deletion of TIPARP, a Negative Regulator of the Aryl Hydrocarbon Receptor, Is Sufficient to Increase Sensitivity to Dioxin-Induced Wasting Syndrome.
Loss of the Mono-ADP-ribosyltransferase, Tiparp, Increases Sensitivity to Dioxin-induced Steatohepatitis and Lethality.
Metabolic roles of poly(ADP-ribose) polymerases.
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
PARP1-mediated PPAR? poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Fatty Liver, Alcoholic
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Fetal Alcohol Spectrum Disorders
Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.
Fibrosarcoma
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
Role of JNK-1 regulation in the protection of contact-inhibited fibroblasts from oxidative stress.
Friedreich Ataxia
Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34.
Gallbladder Neoplasms
Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells.
Ganglion Cysts
Poly(ADP-ribose) polymerase inhibition improves corneal epithelial innervation and wound healing in diabetic rats.
Gastrointestinal Diseases
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Gastrointestinal Neoplasms
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Genetic Diseases, Inborn
The function of poly (ADP-ribosylation) in DNA breakage and rejoining.
Giant Cell Tumors
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Glioblastoma
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.
Associations between polymorphisms in DNA repair genes and glioblastoma.
Caspase-dependent signaling underlies glioblastoma cell death in response to the fungal metabolite, fusarochromanone.
Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells.
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity.
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Discovery of a perinecrotic 60 kDa MDM2 isoform within glioma spheroids and glioblastoma biopsy material.
Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models.
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition.
Glioblastoma multiforme: overview of current treatment and future perspectives.
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme.
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy.
Interleukin-4 Enhances PARP-Dependent DNA Repair Activity In Vitro.
Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model.
Luteolin Decreases Epidermal Growth Factor Receptor-Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines.
MEG-3-mediated Wnt/?-catenin signaling pathway controls the inhibition of tunicamycin-mediated viability in glioblastoma.
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors.
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.
PARP-1 protein expression in glioblastoma multiforme.
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.
PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation.
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation.
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Quercetin Increases the Efficacy of Glioblastoma Treatment Compared to Standard Chemoradiotherapy by the Suppression of PI-3-Kinase-Akt Pathway.
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Radioiodinated PARP1 tracers for glioblastoma imaging.
Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation.
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP.
Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo.
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.
Temozolomide: Mechanisms of Action, Repair and Resistance.
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells.
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Glioma
2'-Hydroxy C16-Ceramide Induces Apoptosis-Associated Proteomic Changes in C6 Glioma Cells.
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.
A novel selenadiazole derivative induces apoptosis in human glioma cells by dephosphorylation of AKT.
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
AG490 influences UCN-01-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Association and interactions between DNA repair gene polymorphisms and adult glioma.
Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis.
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors.
Betulinic acid derivative B10 inhibits glioma cell proliferation through suppression of SIRT1, acetylation of FOXO3a and upregulation of Bim/PUMA.
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Contribution of caspase-independent pathway to apoptosis in malignant glioma induced by carbon ion beams.
Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS.
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas.
Doxorubicin-mediated apoptosis in glioma cells requires NFAT3.
Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis.
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
Fucoxanthin induces apoptosis in human glioma cells by triggering ROS-mediated oxidative damage and regulating MAPKs and PI3K/AKT pathways.
Genetic advances in glioma: susceptibility genes and networks.
Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1.
H2O2-induced cell death in human glioma cells: role of lipid peroxidation and PARP activation.
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase.
Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study.
Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells.
Involvement of poly(ADP-ribose) polymerase-1 in Chinese patients with glioma: a potential target for effective patient care.
JNK Activation Contributes to Oxidative Stress-Induced Parthanatos in Glioma Cells via Increase of Intracellular ROS Production.
Large-conductance K+ channel openers induce death of human glioma cells.
Linarin suppresses glioma through inhibition of NF-?B/p65 and up-regulating p53 expression in vitro and in vivo.
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.
N-methylpurine DNA glycosylase and DNA polymerase {beta} modulate BER inhibitor potentiation of glioma cells to temozolomide.
NADPH treatment decreases C6 glioma cell survival by increasing oxidative stress.
Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway.
NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.
Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway.
Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways.
Oxidative stress and PARP activation mediate the NADH-induced decrease in glioma cell survival.
Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B.
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
PARP1 expression in pediatric central nervous system tumors.
Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target.
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes.
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.
Rhaponticum carthamoides transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage.
Rho/ROCK pathway as a target of tumor therapy.
Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk.
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma.
Tetrandrine and caffeine modulated cell cycle and increased glioma cell death via caspase-dependent and caspase-independent apoptosis pathways.
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
The transcription factor Forkhead box P3 (FoxP3) is expressed in glioma cells and associated with increased apoptosis.
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.
[PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Gliosarcoma
Cellular regulation of poly(ADP) ribosylation of proteins. I. Comparison of hepatocytes, cultured cells and liver nuclei and the influence of varying concentrations of NAD.
Glomerulonephritis
Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation.
Glomerulonephritis, IGA
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura.
Glucose Intolerance
Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes.
Graft vs Host Disease
Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney Transplantation.
Graves Disease
Association of PARP-1, NF-?B, NF-?BIA and IL-6, IL-1? and TNF-? with Graves Disease and Graves Ophthalmopathy.
Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Chinese patients with Graves Disease and Graves Ophthalmopathy.
Graves Ophthalmopathy
Association of PARP-1, NF-?B, NF-?BIA and IL-6, IL-1? and TNF-? with Graves Disease and Graves Ophthalmopathy.
Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Chinese patients with Graves Disease and Graves Ophthalmopathy.
Head and Neck Neoplasms
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-?B interactions.
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427.
Photodynamic therapy (PDT) resistance by PARP1 regulation on PDT-induced apoptosis with autophagy in head and neck cancer cells.
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Heart Arrest
Inhibition of poly(adp-ribose) polymerase reduces cardiomyocytic apoptosis after global cardiac arrest under cardiopulmonary bypass.
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase.
Neuronal accumulation of poly(ADP-ribose) after brain ischaemia.
Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest.
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.
Heart Diseases
1,25(OH)2 D3 improves cardiac dysfunction, hypertrophy and fibrosis through PARP1/SIRT1/mTOR related mechanisms in Type 1 diabetes.
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
PARP1 induces cardiac fibrosis by mediating mTOR activity.
Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.
[Research progress of poly (ADP-ribose) polymerase-1 in cardiac diseases.]
Heart Failure
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.
Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure.
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.
Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.
Myocardial cell death and regeneration during progression of cardiac hypertrophy to heart failure.
Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: Pathophysiological implications and therapeutic potential.
Nitrosative stress and pharmacological modulation of heart failure.
Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure.
PARP inhibition and postinfarction myocardial remodeling.
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
PARP-1 inhibition attenuates cardiac fibrosis induced by myocardial infarction through regulating autophagy.
PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.
PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3? and several PKC isoforms.
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure.
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity.
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
The Promise of Proteomics for the Study of ADP-Ribosylation.
Hematologic Neoplasms
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.